In This Story
Global Innovative Platforms Inc (GIPL0.00%). has submitted its Form 10-K filing for the fiscal year ended September 30, 2024.
The filing reports that the company is engaged in the business of testing breath to detect and assist in the treatment of disease, focusing on advancing animal health through breath analysis and air quality technology.
Global Innovative Platforms is developing non-invasive diagnostic tools using proprietary technologies, 'VOCAM Plus' and 'FROG,' for detecting diseases and monitoring environmental conditions.
The company is prioritizing the development of a breath test to detect heartworm in dogs, which it believes can also be used to identify response to therapy.
Global Innovative Platforms has not recorded any revenue for the years ended September 30, 2024, and 2023, and has an accumulated deficit of $537,213 as of September 30, 2024.
The company reported a net loss of $136,197 for the year ended September 30, 2024, compared to a net loss of $282,786 in the previous year.
The company has identified several opportunities for its technology, including detecting potentially toxic environmental and food conditions for animals.
Global Innovative Platforms is in the development stage of its Heartworm Breath Test and plans to complete verification and validation studies in 2025.
The company has entered into a Patent and Know-How License Agreement with Defiant Technologies Inc., granting it exclusive rights to certain patents and know-how related to animal testing.
Global Innovative Platforms acknowledges its dependence on additional financing to meet its ongoing operating expenses and to develop its business operations.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Global Innovative Platforms Inc annual 10-K report dated December 30, 2024. To report an error, please email earnings@qz.com.